CDK12 and posterior cortical atrophy: Also, retrospective studies have presented evidence for CDK12 alterations as another non–PARPi-sensitizing marker.55,56 A multicenter study did not find any meaningful change of clinical outcome in a PCa cohort that was given PARPi with CDK12 alterations.55 Patients with CDK12-mutated PCa instead show potential sensitivity to PD-1 inhibitors.55